Lista de obras -

4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia

artículo científico publicado en 2003

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab

artículo científico publicado en 2016

A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma

artículo científico publicado en 2011

A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma

artículo científico publicado en 2012

A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost

artículo científico publicado en 2008

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma

artículo científico publicado en 2011

Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice

artículo científico publicado en 2007

Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.

artículo científico publicado en 2010

Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia

artículo científico publicado en 2002

Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study

artículo científico publicado en 2012

Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing

artículo científico publicado en 2009

Bevacizumab and daily temozolomide for recurrent glioblastoma

artículo científico publicado en 2011

Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration

artículo científico publicado en 2009

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas

artículo científico publicado en 2008

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

artículo científico publicado en 2007

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series

artículo científico publicado en 2012

Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma

artículo científico publicado en 2011

Chemotherapy and novel therapeutic approaches in malignant glioma

artículo científico publicado en 2005

Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial

artículo científico publicado en 2013

Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants

artículo científico publicado en 2002

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

artículo científico publicado en 2010

Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma

artículo científico publicado en 2008

Everolimus tablets for patients with subependymal giant cell astrocytoma

artículo científico publicado en 2011

Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma

artículo científico publicado en 2011

Experience with irinotecan for the treatment of malignant glioma

artículo científico publicado en 2008

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma ⬇️

artículo científico publicado el 10 de diciembre de 2010

High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes

artículo científico publicado en 2002

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma ⬇️

artículo científico publicado el 4 de octubre de 2010

Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma

artículo científico publicado en 2008

Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082.

artículo científico publicado en 2009

Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma

scientific article published on 01 June 2004

Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF

scientific article published on 01 April 2002

Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans

artículo científico publicado en 2011

Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells

scientific article published on 01 January 2002

Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results

artículo científico publicado en 2006

Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients

artículo científico publicado en 2011

Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy

artículo científico publicado en 2009

Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution

artículo científico publicado en 2007

Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma

artículo científico publicado en 2012

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma

artículo científico publicado en 2006

Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma

artículo científico publicado en 2004

Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma

artículo científico publicado en 2009

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

artículo científico publicado en 2011

Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma

artículo científico publicado en 2004

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

artículo científico publicado en 2009

Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia

artículo científico publicado en 2003

Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma

artículo científico publicado en 2009

Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma

artículo científico publicado en 2011

Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma

artículo científico publicado en 2005

Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma

artículo científico publicado en 2009

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

artículo científico publicado en 2005

Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.

artículo científico publicado en 2018

Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma

artículo científico publicado en 2015

Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer

artículo científico publicado en 2004

Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme

artículo científico publicado en 2006

Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma

artículo científico publicado en 2012

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma

artículo científico publicado en 2011

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

artículo científico publicado en 2011

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas

artículo científico publicado en 2007

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme

artículo científico publicado en 2005

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

artículo científico publicado en 2010

Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).

artículo científico publicado en 2016

Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme

artículo científico publicado en 2009

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

artículo científico publicado en 2010

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

artículo científico publicado en 2007

Phase II trial of gefitinib in recurrent glioblastoma

artículo científico publicado en 2003

Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy

artículo científico publicado en 2009

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma

artículo científico publicado en 2009

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma

artículo científico publicado en 2013

Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation

artículo científico publicado en 2004

Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and N

artículo científico publicado en 2005

Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis

artículo científico publicado en 2013

Pulmonary sarcoidosis following stem cell transplantation: is it more than a chance occurrence?

artículo científico publicado en 2004

Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme

artículo científico publicado en 2009

Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study

artículo científico publicado en 2010

Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas

artículo científico publicado en 2011

Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma

artículo científico publicado en 2008

Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.

artículo científico publicado en 2006

Temozolomide in children with progressive low-grade glioma

artículo científico publicado en 2007

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

artículo científico publicado en 2015

The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma

artículo científico publicado en 2011

Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients

artículo científico publicado en 2009

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan

scientific article published on January 2008

Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy

artículo científico publicado en 2010

Unrelated umbilical cord blood transplantation in adult patients

artículo científico publicado en 2003

Lista de obras de

4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab

A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma

A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma

A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma

Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice

Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.

Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia

Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study

Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing

Bevacizumab and daily temozolomide for recurrent glioblastoma

Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series

Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma

Chemotherapy and novel therapeutic approaches in malignant glioma

Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial

Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma

Everolimus tablets for patients with subependymal giant cell astrocytoma

Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma

Experience with irinotecan for the treatment of malignant glioma

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma ⬇️

High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma ⬇️

Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma

Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082.

Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma

Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF

Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans

Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells

Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results

Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients

Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy

Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution

Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma

Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma

Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia

Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma

Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma

Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma

Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.

Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma

Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer

Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme

Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).

Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

Phase II trial of gefitinib in recurrent glioblastoma

Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma

Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation

Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and N

Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis

Pulmonary sarcoidosis following stem cell transplantation: is it more than a chance occurrence?

Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme

Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study

Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas

Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma

Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.

Temozolomide in children with progressive low-grade glioma